Literature DB >> 6935685

Anti-gamete monoclonal antibodies synergistically block transmission of malaria by preventing fertilization in the mosquito.

J Rener, R Carter, Y Rosenberg, L H Miller.   

Abstract

Experiments from our laboratory previously demonstrated that infected chickens immunized with gametes of the avian malaria parasite Plasmodium gallinaceum were no longer infectious to the mosquito vector Aedes aegypti and that this transmission-blocking immunity was mediated by antibody. To identify those antigens that are the targets of transmission-blocking immunity, hybrid mouse cell lines secreting monospecific antibodies to surface antigens on male and female gametes of P. gallinaceum have been produced. We describe two such anti-gamete antibodies, 10G3 and 11C7, which act synergistically both to agglutinate male gametes in vitro and to suppress infectivity of parasitized blood fed to mosquitoes. In the presence of a mixture of these antibodies, the male gametes became agglutinated during gametogenesis and failed to detach from the residual body of the gametocyte. In the presence of either antibody alone, the male gametes readily detached during gametogenesis. Neither antibody alone mediated more than a slight reduction in infectivity of gametocytes to mosquitoes. Although both 10G3 and 11C7 recognize surface antigens on both male and female gametes, agglutination and prevention of detachment of the male gametes from the residual body appears to be the primary mechanism by which the mixture of these antibodies prevents fertilization.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6935685      PMCID: PMC350376          DOI: 10.1073/pnas.77.11.6797

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Successful immunization against the sexual stages of Plasmodium gallinaceum.

Authors:  R W Gwadz
Journal:  Science       Date:  1976-09-17       Impact factor: 47.728

3.  Plasmodium gallinaceum: transmission-blocking immunity in chickens. I. Comparative immunogenicity of gametocyte- and gamete-containing preparations.

Authors:  R Carter; R W Gwadz; F M McAuliffe
Journal:  Exp Parasitol       Date:  1979-04       Impact factor: 2.011

4.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

5.  Immunisation against gametes and asexual erythrocytic stages of a rodent malaria parasite.

Authors:  K N Mendis; G A Targett
Journal:  Nature       Date:  1979-02-01       Impact factor: 49.962

6.  Plasmodium gallinaceum: Transmission-blocking immunity in chickens. II. The effect of antigamete antibodies in vitro and in vivo and their elaboration during infection.

Authors:  R Carter; R W Gwadz; I Green
Journal:  Exp Parasitol       Date:  1979-04       Impact factor: 2.011

7.  Current prospects and problems for a malaria vaccine.

Authors:  L H Miller
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

8.  Hybrid plasmacytoma production: fusions with adult spleen cells, monoclonal spleen fragments, neonatal spleen cells and human spleen cells.

Authors:  R H Kennett; K A Denis; A S Tung; N R Klinman
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

9.  Malaria transmission blocked by immunisation with gametes of the malaria parasite.

Authors:  R Carter; D H Chen
Journal:  Nature       Date:  1976-09-02       Impact factor: 49.962

10.  Malaria immunization in Rhesus monkeys. A vaccine effective against both the sexual and asexual stages of Plasmodium knowlesi.

Authors:  R W Gwadz; I Green
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

  10 in total
  19 in total

1.  A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.

Authors:  A W Stowers; D B Keister; O Muratova; D C Kaslow
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Analysis of immunity induced by the affinity-purified 21-kilodalton zygote-ookinete surface antigen of Plasmodium berghei.

Authors:  N Tirawanchai; L A Winger; J Nicholas; R E Sinden
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

3.  The dichotomy (generation of MAbs with functional heterogeneity) in antimalarial immune response in vaccinated/protected mice: a new concept in our understanding of the protective immune mechanisms in malaria.

Authors:  Prati Pal Singh; Bhanu Prakash
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 4.  The biology of Plasmodium in the mosquito.

Authors:  R E Sinden
Journal:  Experientia       Date:  1984-12-15

5.  Plasmodium knowlesi: persistence of transmission blocking immunity in monkeys immunized with gamete antigens.

Authors:  R W Gwadz; L C Koontz
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

Review 6.  Monoclonal antibodies against microorganisms.

Authors:  R A Polin
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

7.  Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi.

Authors:  J A Deans; T Alderson; A W Thomas; G H Mitchell; E S Lennox; S Cohen
Journal:  Clin Exp Immunol       Date:  1982-08       Impact factor: 4.330

Review 8.  Malaria: immunity and prospects for vaccination.

Authors:  M Hommel
Journal:  West J Med       Date:  1981-10

Review 9.  The march toward malaria vaccines.

Authors:  Stephen L Hoffman; Johan Vekemans; Thomas L Richie; Patrick E Duffy
Journal:  Vaccine       Date:  2015-08-29       Impact factor: 3.641

Review 10.  The March Toward Malaria Vaccines.

Authors:  Stephen L Hoffman; Johan Vekemans; Thomas L Richie; Patrick E Duffy
Journal:  Am J Prev Med       Date:  2015-12       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.